Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect

Figures & data

Table 1. Particle size, surface charge and drug loading of NLC.

Samples	Particle size (nm)	PDI	Zeta potential (mV)	DLC of PTX (%)	DLC of DOX (%)	DLE of PTX (%)	DLE of DOX (%)
NLC	126.9 ± 3.1	0.12 ± 0.03	+45.1 ± 2.7	/	/	/	/
PTX NLC	125.4 ± 3.6	0.14 ± 0.04	+37.8 ± 2.5	18.5 ± 1.9	/	82.6 ± 4.2	/
DOX NLC	128.1 ± 3.3	0.13 ± 0.03	+33.9 ± 2.3	/	10.1 ± 1.5	/	85.3 ± 3.9
PTX-DOX NLC	129.3 ± 4.2	0.18 ± 0.05	+26.6 ± 3.2	12.3 ± 1.6	9.5 ± 1.1	81.9 ± 4.4	83.7 ± 4.1

Figure 1. Accumulated PTX and DOX release profiles: (A) PTX release from PTX-DOX NLC, (B) PTX release from PTX NLC, (C) DOX release from PTX-DOX NLC, (D) DOX release from DOX NLC.

Figure 2. MTT assay of NLC and free drug formulations evaluated in NCL-H460 cells.

Table 2. IC₅₀ values of free drugs and NLC on NCL-H460 cells.

Formulations	IC50 for PTX (μM)	IC50 for DOX (μM)
Free PTX	0.193 ± 0.021	/
Free DOX	/	0.176 ± 0.019
PTX NLC	0.062 ± 0.012	/
DOX NLC	/	0.059 ± 0.009
PTX-DOX NLC (1/5)	0.032 ± 0.008	0.161 ± 0.021
PTX-DOX NLC (1/2)	0.042 ± 0.009	0.084 ± 0.013
PTX-DOX NLC (1/1)	0.021 ± 0.006	0.021 ± 0.006
PTX-DOX NLC (2/1)	0.051 ± 0.011	0.026 ± 0.007
PTX-DOX NLC (5/1)	0.141 ± 0.017	0.028 ± 0.010

Figure 3. The tumor growth curves of different formulations.

Figure 4. The tumor inhibition rates of different formulations.